retatrutide phase 2 trial Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide produces up to 30.3%

But if that doesnt happen, we may finally have a medication that will do for obesity what Prozac did for depression

What the Research Suggests About Weight Regain Clinical research supports the idea that ongoing management matters

B., Impact of Semaglutide and Tirzepatide Administration on Weight in Women With Stage IIII Breast Cancer, Journal of Clinical Oncology 42 (2024): e24140

Thank you for sharing, Bryce

This period is characterized by careful dosage titration, designed to acclimate your body to the medication and minimize potential side effects

When your appetite window opens for 30 minutes and you know it could close at any time, the last thing you want to do is cook